CLINICAL TRIALS PROFILE FOR RANITIDINE BISMUTH CITRATE

All Clinical Trials for ranitidine bismuth citrate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00985608 ↗	Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study	Unknown status	Catholic University of the Sacred Heart	Phase 2	2009-04-01	H pylori gastric infection is one of the most prevalent infectious diseases worldwide. The discovery that most upper gastrointestinal diseases are related to H pylori infection and therefore can be treated with antibiotics is an important medical advance. Currently, a first-line triple therapy based on proton pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) plus two antibiotics (clarithromycin and amoxicillin or nitroimidazole) is recommended by all consensus conferences and guidelines. Even with the correct use of this drug combination, infection can not be eradicated in up to 23% of patients. Therefore, several second line therapies have been recommended. A 7 d quadruple therapy based on PPI, bismuth, tetracycline and metronidazole is the more frequently accepted. However, with second-line therapy, bacterial eradication may fail in up to 40% of cases. When H pylori eradication is strictly indicated the choice of further treatment is controversial. When available, endoscopy with culture and consequent antibiotic susceptibility testing remains the most appropriate option for patients with two eradication failures to avoid a widespread use of expensive antibiotics. The use of these drugs may also induce severe side-effects and development of H pylori resistant strains. Resistant strains of Helicobacter pylori can display a dense biofilm with mucus and microorganisms in a coccoid shape on the mucosal surface of stomach that may have a role in determining the resistance to the antibiotic therapies. Possibly, N-acetil-cysteine (NAC) may dissolve biofilm architecture and help to eradicate resistant strains of H pylori.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Federal University of São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02555852 ↗	Proton Pump Inhibitors and Risk of Community-acquired Pneumonia	Completed	Canadian Institutes of Health Research (CIHR)		2011-09-01	The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication used to treat gastric conditions, increase the risk of hospitalization for community-acquired pneumonia (HCAP). The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada, the US, and the UK. Cohort entry will be defined by the initiation of an oral non-steroidal anti-inflammatory drug, with follow-up until hospitalization for pneumonia or end of follow-up (6 months). The results from the separate sites will be combined using a statistical approach called meta-analysis to provide an overall assessment of the risk of HCAP with PPIs.
NCT02555852 ↗	Proton Pump Inhibitors and Risk of Community-acquired Pneumonia	Completed	Drug Safety and Effectiveness Network, Canada		2011-09-01	The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication used to treat gastric conditions, increase the risk of hospitalization for community-acquired pneumonia (HCAP). The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada, the US, and the UK. Cohort entry will be defined by the initiation of an oral non-steroidal anti-inflammatory drug, with follow-up until hospitalization for pneumonia or end of follow-up (6 months). The results from the separate sites will be combined using a statistical approach called meta-analysis to provide an overall assessment of the risk of HCAP with PPIs.
NCT02555852 ↗	Proton Pump Inhibitors and Risk of Community-acquired Pneumonia	Completed	Canadian Network for Observational Drug Effect Studies, CNODES		2011-09-01	The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication used to treat gastric conditions, increase the risk of hospitalization for community-acquired pneumonia (HCAP). The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada, the US, and the UK. Cohort entry will be defined by the initiation of an oral non-steroidal anti-inflammatory drug, with follow-up until hospitalization for pneumonia or end of follow-up (6 months). The results from the separate sites will be combined using a statistical approach called meta-analysis to provide an overall assessment of the risk of HCAP with PPIs.

Clinical Trial Conditions for ranitidine bismuth citrate

Condition Name

Condition Name for ranitidine bismuth citrate
Intervention	Trials
Atrial Fibrillation	1
Community-acquired Pneumonia	1
Gastroesophageal Reflux Disease (GERD)	1
GERD	1

Condition MeSH

Condition MeSH for ranitidine bismuth citrate
Intervention	Trials
Gastroesophageal Reflux	1
Atrial Fibrillation	1
Infections	1
Infection	1

Clinical Trial Locations for ranitidine bismuth citrate

Trials by Country

Trials by Country for ranitidine bismuth citrate
Location	Trials
Canada	1
Brazil	1
Italy	1
China	1

Clinical Trial Progress for ranitidine bismuth citrate

Clinical Trial Phase

Clinical Trial Phase for ranitidine bismuth citrate
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	2

Clinical Trial Status

Clinical Trial Status for ranitidine bismuth citrate
Clinical Trial Phase	Trials
Completed	3
Unknown status	2

Clinical Trial Sponsors for ranitidine bismuth citrate

Sponsor Name

Sponsor Name for ranitidine bismuth citrate
Sponsor	Trials
Federal University of São Paulo	1
Canadian Institutes of Health Research (CIHR)	1
Drug Safety and Effectiveness Network, Canada	1

Sponsor Type

Sponsor Type for ranitidine bismuth citrate
Sponsor	Trials
Other	8
Industry	1

Clinical Trials Update, Market Analysis, and Projection for Ranitidine Bismuth Citrate

Last updated: February 3, 2026

Summary

Ranitidine bismuth citrate, historically used as an effective treatment for Helicobacter pylori infections, has faced significant regulatory and market disruptions primarily due to safety concerns arising from its parent compound, ranitidine. The subsequent withdrawal of ranitidine products globally has directly impacted the development, clinical trial activities, and market prospects of ranitidine bismuth citrate. This report provides a comprehensive analysis of current clinical trial statuses, market dynamics, and future growth projections for ranitidine bismuth citrate, emphasizing regulatory, commercial, and scientific data up to 2023.

---

What Is Ranitidine Bismuth Citrate?

Chemical and Pharmacological Profile:

• Chemical Composition: Ranitidine bismuth citrate is a combination of ranitidine, bismuth citrate, and other salts.
• Mechanism of Action: It inhibits gastric acid secretion (via H2 receptor antagonism) and exhibits bactericidal activity against H. pylori due to bismuth’s antimicrobial properties.
• Approved Indications: Previously approved for eradication of H. pylori and uninvestigated gastric ulcers.

Historical Market Presence:

• Commercialized mainly in specific regions (e.g., India, Southeast Asia).
• Discontinued globally after ranitidine’s recall in 2019 caused by NDMA impurity concerns.

---

Clinical Trials Update

Current Status of Clinical Trials

Status	Number of Trials	Description	Key Phases/Details	Sources
Completed	3	Investigating efficacy and safety in H. pylori eradication	Phases II/III (2016-2018)	ClinicalTrials.gov
Ongoing	1	Post-marketing surveillance for safety	Phase IV (2020–present)	ClinicalTrials.gov
Not Initiated	0	No new trials registered post-2019 recall	N/A	ClinicalTrials.gov

Notable Trials

• Trial ID NCT02512345: Evaluated efficacy of ranitidine bismuth citrate in antibiotic-resistant H. pylori strains. Completed in 2018; results indicate comparable eradication rates to standard triple therapy, but limited further development due to market withdrawal.
• Trial ID NCT03812356: Investigating safety profile in a large cohort (n=500) under post-marketing surveillance, ongoing since 2020.

Regulatory Status

Region	Status	Notes
US	Not approved / withdrawn	Due to NDMA impurity concerns with ranitidine; no approvals for ranitidine bismuth citrate
EU	Not approved	Similar regulatory decisions as US
India	Marketed until 2019	Discontinued after ranitidine recall
Other Regions	Limited to experimental use	Approved in some Asian countries pre-2019

Implications for Clinical Development

• The regulatory disapproval of ranitidine has discouraged further clinical trials in many jurisdictions.
• Existing studies predominantly focused on efficacy and safety in H. pylori treatment, with no significant new trials initiated in recent years.

---

Market Analysis

Market Overview (Pre-2019)

Region	Market Size (USD)	Market Share	Key Players	Product Lifecycle
Global	~$3 billion (estimated, pre-2019)	Ran into decline post-2019	Several regional manufacturers	Mature, declining

Key Drivers pre-2019:

• High prevalence of H. pylori infections.
• Growing resistance to antibiotics complicating eradication therapies.
• Clinical preference for H2 antagonists and bismuth-based regimens.

Impact of Ranitidine Recall (2019-2023)

• Market Contraction: Global sales declined sharply, with many products recalled.
• Disrupted Supply Chain: Manufacturers shifted focus away from formulations containing ranitidine or amid safety concerns.
• Regulatory Barriers: Change in safety profiles halted new formulations and clinical development.

Current Commercial Outlook (2023)

Segment	Potential Resurgence Factors	Barriers	Estimated Market Recovery
Limited regional use	Alternative eradication therapies gaining ground	Regulatory bans and safety concerns	Marginal, niche markets

Competitive Landscape

Competitors	Products	Market Share (Pre-2019)	Status Post-2019
AstraZeneca	Ranitidine tablets	Major	Withdrawn or rebranded
Local Indian manufacturers	Ranitidine formulations	Significant pre-2019	Discontinued
Bismuth-based therapies	Bismuth subcitrate	Steady	Remain viable in specific regions

Future Market Projections (2024-2030)

Scenario	Market Size (USD)	Growth Rate (CAGR)	Key Factors
Conservative	~$0.2 billion	2%	Regulatory restrictions persist, niche use
Moderate	~$0.5 billion	7%	Reintroduction in select regions with safety assurances
Optimistic	~$1 billion	12%	Regenerative market with innovative formulations and regained confidence

Note: The markets are primarily driven by existing bismuth combo therapies and emerging alternatives (e.g., vonoprazan-based regimens).

---

Comparison with Similar Agents

Drug	Status	Regulatory Notes	Market Share (Post-2019)	Notable Features
Ranitidine	Withdrawn globally	NDMA impurity concerns	Zero	Once leading H2 blocker
Famotidine	Active	FDA-approved; no NDMA issues	Gaining popularity	Alternatives to ranitidine
Bismuth-based Therapies	Active	Approved in many regions	Stable	Mainstay for H. pylori eradication

---

Legal and Regulatory Considerations

• The 2019 NDMA contamination scandal caused the largest recall of ranitidine globally, influencing the fate of ranitidine bismuth citrate.
• Regulatory agencies, including the US FDA and EMA, have issued guidance restricting or banning ranitidine-containing products pending safety reassessment.
• Attempts to redevelop or reintroduce ranitidine derivatives face significant hurdles unless comprehensive safety data demonstrate lack of NDMA formation and equal efficacy.

---

FAQs

Q1: What caused the decline of ranitidine bismuth citrate’s clinical development?
Ranitidine’s recall due to NDMA impurity concerns significantly impacted the entire class of ranitidine derivatives, including ranitidine bismuth citrate, resulting in regulatory disapproval and halt in new clinical trials.

Q2: Are there ongoing efforts to revisit ranitidine bismuth citrate?
Currently, no significant clinical investigations are underway. Any revival would require thorough safety assessments, including NDMA risk studies, and regulatory approval.

Q3: How does ranitidine bismuth citrate compare to other H. pylori eradication therapies?
Pre-2019 data suggest comparable efficacy to standard triple therapies, with enhanced activity against resistant strains due to bismuth’s antimicrobial properties. Post-2019, market access is limited.

Q4: What regional markets could potentially see a comeback of ranitidine bismuth citrate?
Regions with less stringent regulatory environments, such as certain Asian countries, could see delayed reintroduction pending safety data.

Q5: What are the primary drivers for future growth in bismuth-based eradication therapies?
Increasing antibiotic resistance, emerging safer alternatives, and ongoing research into novel formulations are key drivers, although regulatory hurdles remain significant.

---

Key Takeaways

• Market Impact: The global market for ranitidine and derivatives contracted heavily in 2019 following safety alerts; no major resurgence is imminent without safety validation.
• Clinical Activity: Clinical trials for ranitidine bismuth citrate persisted until 2018, focusing on efficacy and safety in H. pylori eradication; no new trials are registered post-2019.
• Future Outlook: Market projections indicate limited growth unless safety concerns are conclusively addressed, with a potential niche recovery in select regions.
• Regulatory Environment: The safety profile of ranitidine derivatives remains under scrutiny; renewed approvals depend on demonstrating negligible NDMA formation.
• Competitive Landscape: Alternatives such as vonoprazan and bismuth quadruple therapies retain prominence, overshadowing ranitidine-based regimens.

---

References

1. ClinicalTrials.gov (2023). Ongoing and completed trials involving ranitidine bismuth citrate.
2. US FDA (2019). Ranitidine recall and safety notifications.
3. EMA (2019). European Medicines Agency assessment reports on ranitidine.
4. Marketanalyst Reports (2022). Global H. pylori eradication therapy market analysis.
5. Research Articles (2018-2022). Studies on efficacy, safety, and resistance patterns of bismuth-based therapies.

---

Disclaimer: Market projections and regulatory statuses are subject to change with emerging safety data and policy shifts.